Drugs / Measles-mumps-rubella-varicella vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00483574 Background | May 2007 → Jan 2009 | chickenpox, measles, meningococcal meningitis, mumps infectious disease +1 | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Measles-mumps-rubella-varicella vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00483574 ↗ |
| Known as | MMRV: ProQuad | “MMRV: ProQuad” NCT00483574 ↗ |
| Modality | Vaccine | “Measles-mumps-rubella-varicella vaccine” NCT00483574 ↗ |
| Route | Intramuscular | “0.5 mL, intramuscular at 12 months of age” NCT00483574 ↗ |